Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurobiological Tech (NTII) -- Ignore unavailable to you. Want to Upgrade?

To: Apache Indian who wrote (208)	12/19/1997 7:31:00 AM
From: Howard Frederick	Respond to of 1494

// Usually in drug stocks, you buy on rumor and sell on news. Some people use an entirely different approach to choosing the companies they invest in. They will pick a company based on fundamentals. I consider myself in that category. // somebody must know something about these trials, something not positive This is the million dollar question. If this is the case, and it might be, then you are right. There would be absolutely no reason to buy the stock. If it isn't right, then the company is a gamble. I'm not sure myself. In any case, I bought into the company originally because of Memantine, sold most of my position a few months ago (at a loss), and still like the drug. I now have a chance to get more stock very cheap, and if the drug shows efficacy, could still turn a net profit. I hate to give up my convictions now, especially when holding to those convictions could return the greatest profit. Having said all that, last January the results of the CRF Phase II clinical trials for Rheumatoid Arthritis were released. In the couple of weeks prior to the results being released, NTII's stock price trended sharply lower. They then plummeted even more upon the results being released. So, I don't know. It's a huge gamble.